Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)

Intravitreal Aflibercept (Eylea) for Therapy of Choroidal Neovascularization (CNV) and Fibrovascular Proliferation (FVP) in Patients With Pseudoxanthoma Elasticum (PXE)

The purpose of this study is to determine whether Aflibercept (Eylea) is effective in the treatment of choroidal neovascularization and fibrovascular proliferation in patients with pseudoxanthoma elasticum (PXE) in terms of preservation or improvement of visual acuity.

Inclusion Criteria:

• Diagnosis of PXE by moleculargenetic diagnosis and/or skin biopsy
• Diagnosed CNV or FVP
• Age 18-65 years
• Voluntary participation in this study as proven by written informed consent
• Ability to follow study instructions and likely to attend and complete all required visits
• Best corrected visual acuity between 20/400 and 20/20 at treated eye
• Male and female patients with childbearing potential must use an approved contraceptive method (Pearl Index < 1) before and during the trial
• Pre-menopausal female patients with childbearing potential: a negative pregnancy test must be obtained

Exclusion Criteria:

• Subject is unable to understand the nature, scope, significance and consequences of this clinical trial
• Patients with known allergy or hypersensitivity to Eylea or preparations with similar chemical structure
• Treatment in another clinical trial with therapeutic intervention or use of any other investigational medicinal product (IMP) during the trial of within 30 days before enrolment
• Known or persistent abuse of medication, drugs or alcohol
• Women who are pregnant or breast feeding
• Lack of eligibility at discretion of the investigator
• Ocular operations within a month prior to enrolment
• Non-controlled glaucoma
• Active intraocular inflammation or inflammation of ocular adnexa
• Other diseases resulting in distinct visual constraint
• Distinct opacification of optical media
• Distinct subretinal fibrosis and /or atrophy that prevents a relevant treatment effect by Aflibercept at discretion of investigator
• Serious cardiovascular problems or stroke within 6 months before enrolment
• Simultaneous use of other Vascular Endothelial Growth Factor (VEGF)-inhibiting medication (systemic or ocular) within a month prior to enrolment